Pfizer Inc. (NYSE: PFE) continues to showcase potential practice-changing research and next-generation candidates across its robust Oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17 in Barcelona. Data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts, including more than 10 oral and mini-oral presentations, will be presented across the company’s tumor areas and core scientific modalities, as well as a potential treatment for a cancer-related condition..

在9月13日至17日于巴塞罗那举行的2024年欧洲肿瘤内科学会（ESMO）大会上，辉瑞公司（纽约证券交易所：PFE）继续展示其强大的肿瘤学组合中潜在的改变实践的研究和下一代候选人。来自50多个公司赞助，研究者赞助和合作研究摘要的数据，包括10多个口头和小型口头报告，将在公司的肿瘤领域和核心科学模式以及癌症相关疾病的潜在治疗方法中呈现。。

“At this year’s ESMO, we are looking forward to demonstrating our progress toward delivering next-generation biologics and novel combinations that have the potential to be new standards of care for patients,” said Chris Boshoff, Chief Oncology Officer and Executive Vice President, Pfizer. “Our key data presentations highlight our scientific leadership in developing targeted therapies, including small molecules and antibody-drug conjugates, across our core tumor areas, including breast, bladder and thoracic cancers.”.

辉瑞首席肿瘤官兼执行副总裁克里斯·博斯霍夫（ChrisBoshoff）表示：“在今年的ESMO上，我们期待着展示我们在提供下一代生物制剂和新型组合方面取得的进展，这些组合有可能成为患者护理的新标准。”。“我们的关键数据展示突出了我们在开发靶向治疗（包括小分子和抗体-药物偶联物）方面的科学领导力，这些靶向治疗跨越了我们的核心肿瘤领域，包括乳腺癌，膀胱癌和胸癌。”。

“At ESMO, Pfizer will share important data highlighting our commitment to transforming outcomes for patients living with lung cancer, including longer-term follow-up results from the BRAFTOVI + MEKTOVI PHAROS study in

“在ESMO，辉瑞将分享重要数据，突出我们对改变肺癌患者预后的承诺，包括年BRAFTOVI+MEKTOVI PHAROS研究的长期随访结果

BRAF

BRAF

V600E-mutated metastatic non-small cell lung cancer,” said Karin Tollefson, Chief Oncology Medical Officer, Pfizer. “We are also looking forward to sharing progress on our industry-leading pipeline of new molecules, including encouraging early results for two novel, investigational antibody-drug conjugates and preliminary data on a novel combination of Pfizer’s next-generation CDK inhibitors.”.

V600E突变的转移性非小细胞肺癌，”辉瑞首席肿瘤医学官卡林·托勒夫森（KarinTollefson）说。“我们也期待着分享我们业界领先的新分子管道的进展，包括鼓励两种新型研究性抗体-药物偶联物的早期结果以及辉瑞下一代CDK抑制剂新型组合的初步数据。”。

Key research includes a late-breaking presentation of updated results from the pivotal Phase 2 PHAROS* study of BRAFTOVI (encorafenib) + MEKTOVI (binimetinib) in patients with

关键研究包括最新的突破性报告，介绍了关键的第二阶段PHAROS*研究BRAFTOVI（encorafenib）+MEKTOVI（binimetinib）对患者的最新结果

BRAF

BRAF

V600E-mutant metastatic non-small cell lung cancer (mNSCLC). Longer-term efficacy and safety data will be presented, following the initial primary overall response results (ORR) that supported the

V600E突变转移性非小细胞肺癌（mNSCLC）。根据最初的主要总体反应结果（ORR），将提供长期疗效和安全性数据

FDA approval for BRAFTOVI + MEKTOVI in this indication in 2023

2023年FDA批准BRAFTOVI+MEKTOVI用于该适应症

and the recent approval by the European Commission in August 2024. Further, Pfizer will share updated data from the safety lead-in of the ongoing Phase 3 BREAKWATER trial, showing antitumor activity of BRAFTOVI + cetuximab + FOLFIRI in patients with untreated .

以及最近于2024年8月获得欧盟委员会的批准。。

BRAF

BRAF

V600E-mutant metastatic colorectal cancer (mCRC) in a mini-oral presentation.

V600E突变型转移性结直肠癌（mCRC）的迷你口服介绍。

Additionally, Pfizer will present a late-breaking Proffered Paper Presentation on the Phase 2 efficacy and safety results for its GDF-15 inhibitor, ponsegromab, in patients with cancer-associated cachexia, highlighting the company’s commitment to improving the treatment journey for people living with cancer.

此外，辉瑞将发表一篇最新的论文，介绍其GDF-15抑制剂ponsegromab在癌症相关恶病质患者中的2期疗效和安全性结果，突出了该公司对改善癌症患者治疗过程的承诺。

Cancer cachexia is a common, life-threatening wasting condition characterized by severe weight loss. The condition affects patients with advanced cancers and can greatly impact a patient’s ability to tolerate cancer treatment and quality of life. Despite its severity, there are no FDA-approved treatments for cachexia..

癌症恶病质是一种常见的威胁生命的消瘦疾病，其特征是体重严重减轻。这种情况会影响晚期癌症患者，并会极大地影响患者耐受癌症治疗的能力和生活质量。尽管恶病质严重，但尚无FDA批准的恶病质治疗方法。。

i,ii

i、 二

Pfizer will also present early clinical-stage research for a number of priority pipeline areas, including encouraging Phase 1 results of the potential first-in-class antibody-drug conjugate (ADC) candidate SGN-PDL1V (PF-08046054)

辉瑞公司还将针对一些优先管道领域进行早期临床阶段研究，包括潜在的一流抗体-药物偶联物（ADC）候选药物SGN-PDL1V（PF-08046054）的第一阶段令人鼓舞的结果

in NSCLC and head and neck squamous cell carcinoma (HNSCC); initial data for the investigational ADC disitamab vedotin in combination with KEYTRUDA

在NSCLC和头颈部鳞状细胞癌（HNSCC）中；研究性ADC disitamab vedotin联合KEYTRUDA的初始数据

®

®

(pembrolizumab) in human epidermal growth factor receptor 2 (HER2)-expressing locally advanced or metastatic urothelial cancer (la/mUC); and the first data combining atirmociclib, our highly-selective cyclin-dependent kinase 4 (CDK4) inhibitor (CDK4i), with a novel CDK2 inhibitor (CDK2i) in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer (MBC) from a Phase 1 dose-escalation study..

（pembrolizumab）在表达局部晚期或转移性尿路上皮癌（la/mUC）的人表皮生长因子受体2（HER2）中；第一个数据是将我们的高选择性细胞周期蛋白依赖性激酶4（CDK4）抑制剂（CDK4i）与激素受体阳性（HR+）/HER2阴性转移性乳腺癌（MBC）中的新型CDK2抑制剂（CDK2i）相结合的第一阶段剂量递增研究。。

Key ESMO Presentations

ESMO主要演示文稿

Genitourinary Cancer

泌尿生殖系统癌

PADCEV + KEYTRUDA**:

键盘+按键**：

additional analysis from the pivotal EV-302 trial continues to support the combination as a new standard of care for patients with previously untreated la/mUC. An exploratory analysis shows PADCEV + KEYTRUDA

关键的EV-302试验的其他分析继续支持该组合作为先前未经治疗的la/mUC患者的新护理标准。

®

®

showed consistent progression free survival (PFS), overall survival (OS), and ORR versus chemotherapy regardless of Nectin-4 or PD-L1 expression.

无论Nectin-4或PD-L1表达如何，与化疗相比，显示出一致的无进展生存期（PFS），总生存期（OS）和ORR。

Disitamab Vedotin:

Disitamab拖拉机：

preliminary efficacy and safety data for disitamab vedotin in combination with KEYTRUDA highlights Pfizer’s continued commitment to developing novel therapeutics to meet the needs of patients with bladder cancer. Results from the safety run-in of the ongoing Phase 2 trial showed encouraging early efficacy and a safety profile consistent with previously presented data in treatment-naive patients with HER2-expressing la/mUC..

地西他单抗维多汀联合KEYTRUDA的初步疗效和安全性数据突显了辉瑞公司继续致力于开发新疗法以满足膀胱癌患者的需求。正在进行的2期临床试验的安全性试验结果显示，令人鼓舞的早期疗效和安全性与先前提出的HER2表达la/mUC的未接受治疗的患者的数据一致。。

Thoracic Cancer

胸廓癌

SGN-PDL1V (PF-08046054):

SGN-PDL1V（PF-08046054）：

encouraging Phase 1 results will be presented for PDL1V, a novel, investigational vedotin ADC directed to PD-L1-expressing solid tumors. Data from the dose-escalation and dose optimization cohorts of the ongoing Phase 1 study show PDL1V as monotherapy was generally well tolerated with no unexpected adverse events, and encouraging antitumor activity was observed in patients with heavily pretreated NSCLC and HNSCC..

PDL1V是一种针对表达PD-L1的实体瘤的新型研究性vedotin ADC，将呈现令人鼓舞的1期结果。来自正在进行的1期研究的剂量递增和剂量优化队列的数据显示，PDL1V作为单一疗法通常耐受性良好，没有意外的不良事件，并且在经过严重预处理的NSCLC和HNSCC患者中观察到令人鼓舞的抗肿瘤活性。。

Breast Cancer

乳腺癌

Atirmociclib (PF-07220060) + PF-07104091

阿替莫昔布（PF-07220060）+PF-07104091

: initial data from a dose-escalation study evaluating the innovative combination of atirmociclib, a potential first-in-class CDK4-selective inhibitor, with PF-07104091, a novel CDK2-selective inhibitor, showed a manageable safety profile and encouraging efficacy in patients with heavily pretreated HR+/HER2- breast cancer.

：来自剂量递增研究的初始数据评估了潜在的一流CDK4选择性抑制剂阿替莫西利与新型CDK2选择性抑制剂PF-07104091的创新组合，显示出可控的安全性，并且在严重预处理的HR+/HER2患者中具有令人鼓舞的疗效-乳腺癌。

These early results highlight the potential of Pfizer's strategy to advance atirmociclib as a future CDK inhibitor backbone therapy that may address treatment resistance with first generation CDK4/6i, subject to clinical success and regulatory approval. The CDK4i+2i combination is continuing to be explored in an ongoing Phase 1b/2 dose escalation and dose expansion study (NCT05262400)..

这些早期结果突出了辉瑞公司推进阿曲莫西利作为未来CDK抑制剂骨架疗法的策略的潜力，该疗法可能会解决第一代CDK4/6i的治疗耐药性，但需要临床成功和监管部门的批准。CDK4i+2i组合正在进行1b/2期剂量递增和剂量扩展研究（NCT05262400）中继续探索。。

Additional information on the Pfizer-sponsored abstracts, including date and time of presentation, follow in the chart below.

有关辉瑞赞助摘要的其他信息，包括提交日期和时间，请参见下表。

Pfizer is continuing its commitment to help non-scientists understand the latest findings with the development of abstract plain language summaries (APLS) for company-sponsored research being presented at ESMO, which are written in non-technical language. Those interested in learning more can visit .

辉瑞公司继续致力于帮助非科学家了解最新发现，并为ESMO上提交的公司赞助研究开发了抽象简明语言摘要（APL），这些摘要是用非技术语言编写的。有兴趣了解更多信息的人可以访问。

to access the summaries starting September 16, 2024.

从2024年9月16日开始访问摘要。

BREAST CANCER

乳腺癌

Mini Oral Presentation (Abstract 618MO)

小型口头报告（摘要618MO）

Saturday, September 14, 2:45 PM-4:15 PM CEST

9月14日星期六下午2:45-4:15 CEST

Phase 1b/2 first-in-class novel combination trial of next generation CDK4-selective inhibitor PF-07220060 and next generation CDK2-selective inhibitor PF-07104091 in HR+ HER2- metastatic breast cancer and advanced solid tumors

下一代CDK4选择性抑制剂PF-07220060和下一代CDK2选择性抑制剂PF-07104091在HR+HER2转移性乳腺癌和晚期实体瘤中的1b/2期一流新型联合试验

Yap et al

亚普等人

Poster Presentation (Abstract 413P)

海报展示（摘要413P）

Monday, September 16, 9:00 AM-5:00 PM CEST

9月16日星期一上午9:00-下午5:00 CEST

Longitudinal circulating tumor DNA (ctDNA) dynamics in Phase 1/2a study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2− metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors.

第一类CDK4选择性抑制剂PF-07220060的1/2a期研究中的纵向循环肿瘤DNA（ctDNA）动力学与内分泌治疗联合用于HR+/HER2-转移性乳腺癌（mBC）患者，这些患者在先前的CDK4/6抑制剂上取得了进展。

Yap et al

亚普等人

Poster Presentation (Abstract 359P)

海报展示（摘要359P）

Monday, September 16, 9:00 AM-5:00 PM CEST

9月16日星期一上午9:00-下午5:00 CEST

Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study.

palbociclib（PAL）+内分泌治疗（ET）在日本激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）晚期乳腺癌（ABC）患者的一线（1L）或二线（2L）设置：多中心观察性研究。

Poster Presentation (Abstract 354P)

海报展示（摘要354P）

Monday, September 16, 9:00 AM-5:00 PM CEST

9月16日星期一上午9:00-下午5:00 CEST

Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer

CDK4和CDK2选择性抑制剂PF-07220060和PF-07104091分别联合治疗HR+HER2乳腺癌的临床前协同疗效

Anders et al

Anders等人。

Poster Presentation (Abstract 356P)

海报展示（摘要356P）

Monday, September 16, 9:00 AM-5:00 PM CEST

9月16日星期一上午9:00-下午5:00 CEST

Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim Results of the PERFORM study

HR+/HER2-ABC患者palbociclib+内分泌治疗亚组的真实有效性：PERFORM研究的中期结果

Pfeiler et al

Pillar等人

EARLY PIPELINE

早期管道

Oral Presentation, Proffered Paper (Abstract 607O)

口头陈述，提交的论文（摘要607O）

Friday, September 13, 4:00 PM-5:30 PM CEST

9月13日星期五下午4:00-5:30 CEST

Interim results of a Phase 1 study of SGN-PDL1V (PF-08046054) in patients with PDL1-expressing solid tumors

表达PDL1的实体瘤患者SGN-PDL1V（PF-08046054）1期研究的中期结果

Oliva Bernal et al

Oliva Bernal等人。

GASTROINTESTINAL CANCER

胃肠道癌

Mini Oral Presentation (Abstract 515MO)

小型口头报告（摘要515MO）

Saturday, September 14, 2:45 PM-4:15 PM CEST

9月14日星期六下午2:45-4:15 CEST

Encorafenib + cetuximab (EC) + FOLFIRI for

恩可芬尼布+西妥昔单抗（EC）+福立菲

BRAF

BRAF

V600E-mutant metastatic colorectal cancer (mCRC): updated results from the BREAKWATER safety lead-in (SLI)

V600E突变转移性结直肠癌（mCRC）：防波堤安全引入（SLI）的最新结果

Tabernero et al

Tabernero等人

GENITOURINARY CANCER

泌尿生殖系统癌

Mini Oral Presentation (Abstract 1966MO)

小型口头报告（摘要1966MO）

Sunday, September 15, 8:30 AM-10:00 AM CEST

9月15日星期日上午8:30-10:00 CEST

EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)

EV-302：先前未经治疗的局部晚期或转移性尿路上皮癌（la/mUC）中nectin-4表达和对1L enfortumab vedotin（EV）+pembrolizumab（P）反应的探索性分析

Powles et al

波尔斯等人。

Poster Presentation (Abstract 1968P)

海报展示（摘要1968P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Study EV-103 dose escalation/cohort A (DE/A): 5y follow-up of first-line (1L) enfortumab vedotin (EV) + pembrolizumab (P) in cisplatin (cis)-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC)

研究EV-103剂量递增/队列A（DE/A）：顺铂（cis）不合格的局部晚期或转移性尿路上皮癌（la/mUC）一线（1L）enfortumab vedotin（EV）+pembrolizumab（P）的5年随访

Rosenberg et al

罗森伯格等人

Poster Presentation (Abstract 2001P)

海报展示（摘要2001P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial cancer in France: a non-interventional database study

法国局部晚期或转移性尿路上皮癌患者的流行病学和治疗模式：一项非介入性数据库研究

Joly et al

Joly等人

Poster Presentation (Abstract 1638P)

海报展示（摘要1638P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Enzalutamide (ENZA) with or without leuprolide in patients (pts) with high-risk biochemically recurrent (hrBCR) prostate cancer (PC): EMBARK post hoc analysis by age

高危生化复发（hrBCR）前列腺癌（PC）患者（pts）服用或不服用亮丙瑞林的恩扎鲁胺（ENZA）：按年龄进行事后分析

Shore et al

肖尔等人

Poster Presentation (Abstract 1626P)

海报展示（摘要1626P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Incidence of hematologic toxicities in the homologous recombination repair (HRR)-deficient population of the TALAPRO-2 trial and their potential association with germline vs somatic origin of HRR gene alterations

TALAPRO-2试验中同源重组修复（HRR）缺陷人群的血液学毒性发生率及其与HRR基因改变的种系与体细胞起源的潜在关联

Azad et al

Azad等人

Poster Presentation (Abstract 1637P)

海报展示（摘要1637P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Efficacy of talazoparib and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients previously treated with androgen receptor pathway inhibitors (ARPI) or docetaxel – post hoc analysis from both cohorts in TALAPRO-2 study

talazoparib和enzalutamide对先前接受雄激素受体途径抑制剂（ARPI）或多西紫杉醇治疗的转移性去势抵抗性前列腺癌（mCRPC）患者的疗效-TALAPRO-2研究中两个队列的事后分析

Agarwal et al

阿加瓦尔等人

Poster Presentation (Abstract 1633P)

海报展示（摘要1633P）

Sunday, September 15, 9:00 AM-5:00 PM CEST

9月15日星期日上午9:00-下午5:00 CEST

Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

talazoparib（TALA）+enzalutamide（ENZA）与安慰剂（PBO）+ENZA作为转移性去势抵抗性前列腺癌（mCRPC）患者（pts）一线（1L）治疗的3期研究：TALAPRO-2（TP-2）中国队列

Zeng et al

曾等

Mini Oral Presentation (Abstract 1967MO)

小型口头报告（摘要1967MO）

Sunday, September 15, 8:30 AM-10:00 AM CEST

9月15日星期日上午8:30-10:00 CEST

Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 Cohort C

地西他单抗vedotin（DV）联合pembrolizumab（P）治疗（Tx）-未表达HER2的局部晚期或转移性尿路上皮癌（la/mUC）的初步疗效和安全性：RC48G001队列C

Galsky et al

Galsky等人。

MELANOMA

黑色素瘤

Poster Presentation (Abstract 1071TiP)

海报展示（摘要1071TiP）

Saturday, September 14, 9:00 AM-5:00 PM CEST

9月14日星期六上午9:00-下午5:00 CEST

Phase 1 study of the investigational CD228 x 4-1BB costimulatory antibody Anticalin bispecific SGN-BB228 (PF-08046049) in advanced melanoma and other solid tumors

研究性CD228 x 4-1BB共刺激抗体抗碱性双特异性SGN-BB228（PF-08046049）在晚期黑色素瘤和其他实体瘤中的1期研究

Dummer et al

Dummer等人

SUPPORTIVE AND PALLIATIVE CARE

支持和姑息治疗

Oral Presentation, Proffered Paper (Abstract LBA82)

口头报告，提交的论文（摘要LBA82）

Saturday, September 14, 2:45 PM-4:25 PM CEST

9月14日星期六下午2:45-4:25 CEST

Efficacy and safety of ponsegromab, a first-in-class, monoclonal antibody inhibitor of growth differentiation factor-15, in patients with cancer cachexia: A randomized, placebo-controlled, Phase 2 study

ponsegromab是一种一流的生长分化因子-15单克隆抗体抑制剂，对癌症恶病质患者的疗效和安全性：一项随机、安慰剂对照的2期研究

Crawford et al

克劳福德等人

THORACIC CANCER

胸廓癌

Mini Oral Presentation (Abstract LBA56)

小型口头报告（摘要LBA56）

Saturday, September 14, 10:15 AM-11:45 AM CEST

9月14日星期六上午10:15-11:45 CEST

Updated efficacy and safety from the Phase 2 PHAROS study of encorafenib plus binimetinib in patients with

encorafenib联合binimetinib治疗2期PHAROS研究的最新疗效和安全性

BRAF

BRAF

V600E-mutant metastatic NSCLC (mNSCLC)

V600E突变转移性非小细胞肺癌（mNSCLC）

Riely et al

Riely等人。

Poster Presentation (Abstract 1398TiP)

海报展示（摘要1398TiP）

Saturday, September 14, 9:00 AM-5:00 PM CEST

9月14日星期六上午9:00-下午5:00 CEST

Be6A Lung-01, a Phase 3 study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)

Be6A Lung-01，sigvotatug vedotin（SV）的3期研究，sigvotatug vedotin是一种研究性抗体-药物偶联物（ADC）与多西紫杉醇在先前治疗过的非小细胞肺癌（NSCLC）患者（pts）中的对比

Peters et al

彼得斯等人

Poster Presentation (Abstract 1279P)

海报展示（摘要1279P）

Saturday, September 14, 9:00 AM-5:00 PM CEST

9月14日星期六上午9:00-下午5:00 CEST

First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study

亚洲ALK+非小细胞肺癌（NSCLC）患者的一线洛拉替尼与克唑替尼：CROWN研究的5年结果

Wu et al

吴等人

*The PHAROS trial is conducted with support from Pierre Fabre.

*PHAROS试验是在Pierre Fabre的支持下进行的。

**Pfizer and Astellas have a clinical collaboration agreement with Merck to evaluate the combination of PADCEV

**辉瑞（Pfizer）和阿斯特拉斯（Astellas）与默克（Merck）签订了临床合作协议，以评估PADCEV的组合

About Pfizer Oncology

关于辉瑞肿瘤学

At Pfizer Oncology, we are at the forefront of a new era in cancer care. Our industry-leading portfolio and extensive pipeline includes three core mechanisms of action to attack cancer from multiple angles, including antibody-drug conjugates (ADCs), small molecules, bispecific antibodies and other immunotherapy biologics.

在辉瑞肿瘤学，我们处于癌症护理新时代的前沿。我们业界领先的产品组合和广泛的渠道包括从多个角度攻击癌症的三个核心作用机制，包括抗体-药物偶联物（ADC），小分子，双特异性抗体和其他免疫治疗生物制剂。

We are focused on delivering transformative therapies in some of the world’s most common cancers, including breast cancer, genitourinary cancer, hematology-oncology, and thoracic cancers, which includes lung cancer. Driven by science, we are committed to accelerating breakthroughs that help people with cancer globally live better and longer lives..

我们专注于为世界上一些最常见的癌症提供变革性治疗，包括乳腺癌，泌尿生殖系统癌症，血液肿瘤和包括肺癌在内的胸癌。在科学的推动下，我们致力于加速突破，帮助全球癌症患者过上更好、更长的生活。。

About Pfizer: Breakthroughs That Change Patients’ Lives

关于辉瑞：改变患者生活的突破

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines.

在辉瑞，我们应用科学和全球资源，为人们带来治疗，延长并显着改善他们的生活。我们努力为包括创新药物和疫苗在内的保健产品的发现、开发和制造制定质量、安全和价值标准。

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.

辉瑞公司的同事们每天都在发达市场和新兴市场开展工作，促进健康、预防、治疗和治愈，挑战我们这个时代最可怕的疾病。作为世界首屈一指的创新生物制药公司之一，我们与医疗保健提供者、政府和当地社区合作，支持和扩大全球可靠、负担得起的医疗保健服务。

For 175 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at .

175年来，我们一直致力于为所有依赖我们的人带来改变。我们经常在我们的网站上发布对投资者可能很重要的信息。